Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer

BackgroundCurrently, the prognosis for metastatic colorectal cancer (mCRC) remains unfavorable. However, as advancements in local and systemic treatment modalities progress, therapeutic strategies for mCRC are becoming increasingly varied. For patients presenting with a limited number of metastases,...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Wei Qian, Huatang Zhang, Yanhua Mo, Chaoyang Wu, Juntong Liu, Yuyi Pen, Cantu Fang, Jincheng Meng
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2026-02-01
Cyfres:	Frontiers in Oncology
Pynciau:	fruquintinib immunotherapy metastatic colorectal cancer microwave ablation tislelizumab
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1728876/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!